Anxiety, by contrast, was significantly lower in both monitored groups, with the advantage persisting to day 10 in the telephone arm. The source article reports that approximately 1.6 million women in the United States and 1.9 million in Europe undergo the procedure each year, and roughly 80 percent ultimately receive benign results. Nevertheless, patients may experience fear not only of pain but also of what a suspicious imaging finding might mean.

Distress can begin before the procedure and persist while patients wait for pathology results, and pre-biopsy distress has been associated with greater procedural pain and discomfort. Even after a benign result, some patients retain higher levels of distress than people without a history of biopsy. BIO-PSY therefore tested whether a brief, structured remote intervention could identify symptoms early and provide targeted support during the interval surrounding the biopsy and the wait for results.

BIO-PSY was a prospective, open-label, single-center randomized controlled trial. Eligible participants were women aged 18 or older who underwent diagnostic breast biopsy at the cancer center between March 2021 and July 2023. They were allocated in a one-to-one-to-one ratio to the telephone-based patient-reported outcome arm, the electronic patient-reported outcome arm, or the control group receiving standard care.

Randomization was stratified by biopsy modality, Breast Imaging Reporting and Data System classification, and baseline pain below 4 or at least 4 on a 0-to-10 numerical rating scale. Physicians, radiology technicians, and statisticians were blinded to allocation, while patients and psycho-oncologists could not be. The study, registered as NCT04456920, had pain assessed by telephone on day 4 as its primary outcome.

Its sample-size calculation targeted a two-point reduction in mean pain relative to usual care, based on a small departmental pilot of 25 patients whose estimated mean pain score was 5 on the 10-point scale. The two active approaches shared the same symptom thresholds and response strategies. In the telephone arm, a psycho-oncologist called each patient on days 1, 2, and 3 for a semi-structured conversation grounded in cognitive-behavioral therapy.

Most calls lasted about 20 minutes, although sessions ranged from approximately 5 to 40 minutes when anxiety-related concerns required more extensive discussion. In the electronic arm, patients entered pain, anxiety, aesthetic concerns, adverse events, and concomitant treatments into the EXOLIS interface, which took less than four minutes to complete. Automated reminders supported completion, and alerts were generated when predefined thresholds were crossed.

Psycho-oncology staff monitored alerts six days per week, excluding Sundays, and contacted patients who met a threshold within 24 hours. Participants without a smartphone were lent tablets and 4G devices, allowing them to use the electronic pathway. Control patients received routine post-procedure instructions and were advised to contact the department if complications arose, but they had no structured symptom assessment during days 1 to 3.

Thresholds determined the response in both intervention groups. A pain score of 4 or higher triggered tailored advice, including the use of paracetamol and local ice when appropriate, together with discussion of cognitive or environmental strategies that the patient had previously found useful. Anxiety scores of 4 or higher prompted exploration and reframing of the patient’s thoughts, followed by instruction in paced breathing at 0.10 Hz for five minutes three times daily.

Patients reporting substantial aesthetic discomfort could describe their concerns, receive information about the expected course of the change, and discuss further management. Suspected biopsy complications were escalated to the radiology team. During the three intervention days, 18 of the 60 interviewed patients in the telephone arm received tailored management on day 1, seven on day 2, and four on day 3.

These contacts could include pharmacological measures, non-pharmacological interventions, or both. Pain was negligible at both measured time points. On day 4, the median score was 0 in the telephone, electronic, and control groups, with an interquartile range of 0 to 1 and a non-significant between-group result of p = 0.59.

Only three participants, 1.7 percent of those assessed, reported pain intense enough to trigger tailored management. By day 10, the median remained 0 in every arm, and seven patients reported pain of at least 4, again with no significant difference among groups. The investigators said the much lower pain intensity than anticipated created a floor effect that limited their ability to detect a difference in the primary endpoint.

The original calculation had relied on the imprecise estimate from the 25-patient pilot, and that assumption did not hold in the randomized trial. With pain already close to zero across all arms, the study could not establish whether either remote approach had an analgesic advantage over standard care. Anxiety showed the clearest difference between the monitored and usual-care groups.

At day 4, median anxiety scores were 2 in both the telephone and electronic arms, compared with 4 in the control arm, with an overall p value below 0.001. The proportion scoring at least 4 was also significantly lower in each experimental group than in the control group, with adjusted p values below 0.001 for the telephone comparison and 0.005 for the electronic comparison. At day 10, the lower proportion of clinically significant anxiety was maintained in the telephone arm, with an adjusted p value of 0.008, but not in the electronic arm.

Telephone descriptions offered a possible explanation for the different duration of benefit. Psycho-oncologists’ notes suggested that patients’ anxiety was driven less by the biopsy itself than by uncertainty surrounding the diagnostic process while they waited for results. This interpretation was not collected through a formal qualitative analysis and was not based on a direct measure of intolerance of uncertainty, so it remains hypothesis-generating.

Telephone consultations combined symptom assessment with an opportunity to clarify concerns and consider realistic interpretations. The same intervention was also available after an electronic alert, but the telephone arm provided routine contact with a clinician for three consecutive days, including patients whose scores did not cross intervention thresholds. The trial could not determine whether the sustained day-10 difference arose from the frequency of contact, the therapeutic conversation, the timing of support, or another feature of the intervention.

Several secondary outcomes showed no significant between-group differences, while the number of participants receiving tailored management did vary. Median perceived aesthetic impact was 0 in every arm on days 4 and 10, and few participants reported substantial aesthetic concerns. Insomnia Severity Index scores did not differ significantly at day 10, nor did the proportion reaching clinical levels of insomnia.

At day 4, however, tailored management was provided to 28.9 percent of participants: 13.6 percent in the telephone arm, 36.1 percent in the electronic arm, and 36.7 percent in the control group. The overall difference was significant at p = 0.007, with adjusted p values of 0.02 for telephone versus electronic monitoring and 0.01 for telephone versus control. Biopsy complications were rare: two participants experienced bleeding, one in the electronic arm on the day of biopsy and one in the control arm on day 4.

No adverse events were attributed to the study interventions. Between days 1 and 10, 78 women, or 40.6 percent, reported concomitant treatments, with no significant difference among the three groups. Treatments included analgesics, anxiolytics, antidepressants, hypnotics, and other measures or non-pharmacological interventions.

Satisfaction with the study was high overall: the median day-10 satisfaction score was 10, with 57.8 percent of participants giving a score of 10 and 32.4 percent giving a score of 9. The difference between arms was not significant, and the researchers did not formally assess acceptability, preferences for human versus digital contact, cost-effectiveness, or staff workload. The trial also used an open-label design, which could have influenced how patients reported their symptoms.

Its single-center setting and relatively limited sample may restrict generalizability, and anxiety was a secondary outcome in a trial powered primarily to detect a reduction in pain. Anxiety was measured with a single-item numerical rating scale rather than a validated multidimensional instrument, limiting characterization of anxiety beyond its reported intensity. The results should therefore be read as evidence from one open-label, single-center trial of 193 women, not proof that remote monitoring changes every aspect of biopsy care.

The randomized comparison showed a short-term anxiety advantage for both forms of structured remote follow-up and a persistent advantage for the telephone intervention, even though physical pain was uniformly low. The investigators could not isolate the effects of individual components such as cognitive reframing, breathing instruction, scheduled calls, or alert-triggered support, nor directly test diagnostic uncertainty as a mechanism. Broader replication would be needed before drawing conclusions about routine implementation across hospitals and health systems.

The authors proposed future trials with anxiety or distress as the primary outcome, longer follow-up, formal evaluation of diagnostic uncertainty, and assessment of workload, implementation feasibility, cost-effectiveness, and longer-term patient-reported benefits.

Subject of Research: Randomized trial of remote patient-reported outcome monitoring for pain and anxiety after diagnostic breast biopsy

Article Title: Impact of remote management using patient-reported outcomes on pain and anxiety after breast biopsy: the BIO-PSY randomized controlled trial

Article References: Guerdoux, E., Coutant, L., Al Herk, A., Meignant, L., Laffargue, G., Salasc, F., Pibre, J., Blasco, S., Bignon, N., Thomaso, M., & Nougaret, S. (2026). Impact of remote management using patient-reported outcomes on pain and anxiety after breast biopsy: the BIO-PSY randomized controlled trial. Supportive Care in Cancer, 34(11), Article 1140. https://doi.org/10.1007/s00520-026-11349-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11349-8

Keywords: breast biopsy, patient-reported outcomes, anxiety, remote monitoring, psycho-oncology, randomized controlled trial, electronic health, supportive care, breast imaging, diagnostic uncertainty, Impact, remote

Dysarthria is a motor speech disorder affecting people with neurological conditions and is highly prevalent among stroke survivors. Effective treatment requires assessment of severity and speech exercises tailored to the degree of impairment. Traditional speech intervention can face limited access to therapists and low treatment adherence. Whisper-ST1 was developed as a possible component for home-based rehabilitation, with the study focusing on automated severity classification rather than evaluating a complete rehabilitation program.

The researchers built Whisper-ST1 by fine-tuning a pretrained automatic speech recognition model using real-world data alongside traditional research datasets. The model architecture was adapted for the new task, and the researchers used progressive unfreezing to promote flexible adaptation while limiting catastrophic forgetting of relevant speech features. They also applied an ordinal regression loss to reduce the impact of misclassification errors. Ablation experiments examined the contribution of individual pipeline components in isolation.

On real-world samples, Whisper-ST1 produced a per-speaker F1 score of 79% [67%–100%] for dysarthria-severity classification. Its weighted Cohen’s kappa values were 0.814 [0.400–1.000] and 0.878 [0.647–1.000] when compared with the two speech therapists’ ratings, while inter-therapist agreement was 0.851 [0.550–1.000]. Model errors were predominantly between adjacent severity levels, suggesting that the system preserved the ordinal structure of the severity scale. The study therefore demonstrates a proof-of-concept classification approach in heterogeneous audio conditions and provides a foundational step toward AI-assisted tools for remote monitoring and support of dysarthria rehabilitation, but it does not establish the system as a replacement for professional assessment or a complete home rehabilitation intervention.

Subject of Research: Proof-of-concept evaluation of an AI-based audio classification system for dysarthria severity assessment

Article Title: An artificial intelligence-based audio recognition system for dysarthria home-based rehabilitation: A proof-of-concept study

Article References: Sancenon, V., Oh, P. Y. S., Tay, E. K. W., Lee, J. Z. X., Soon, M. L. E., Goh, H. L., Oey, N., & Ta, A. W. A. (2026). An artificial intelligence-based audio recognition system for dysarthria home-based rehabilitation: A proof-of-concept study. PLOS Digital Health, 5(10), e0001794. https://doi.org/10.1371/journal.pdig.0001794

Image Credits: AI Generated

DOI: 10.1371/journal.pdig.0001794

Keywords: dysarthria, artificial intelligence, speech recognition, motor speech disorder, Whisper-ST1, stroke, remote monitoring, ordinal classification, clinical speech assessment, home rehabilitation, artificial, intelligence-based

Virtual wards in the review combined hospital-level care delivered at home with remote monitoring of vital signs, clinical variables and symptoms. The model could be used to avoid hospital admission after referral from an emergency department or to support early discharge from a hospital ward. Eligible participants were adults presenting to an emergency department or admitted with an acute condition, including infections, gastrointestinal disorders and pulmonary embolisms. Studies focused exclusively on chronic-care exacerbations, trauma, psychiatry, primary care, hospice care and COVID-19 were excluded.

Investigators searched MEDLINE, Embase, Cochrane, CINAHL, Web of Science and PubMed for peer-reviewed publications through 28 February 2025. Searches combined terms for hospital-at-home care, virtual wards, admission avoidance and early discharge with terms for acute disease, telemedicine and remote monitoring. English-, Dutch-, French- and German-language trials, cohort and pilot studies, letters to editors and qualitative studies were eligible, with no minimum sample size required. Two reviewers independently screened and extracted the data, resolving disagreements by consensus or consultation with a third reviewer.

The search identified 8,562 unique records, of which 217 were considered potentially eligible during title-and-abstract screening. Twenty-two studies were retained after full-text review. The research populations included 11,476 patients receiving virtual-ward care, 17,336 receiving hospital care and 134 receiving non-technology-enabled hospital-at-home care. Most studies were published between 2018 and 2025. Average ages in virtual-ward cohorts ranged from 54 to 80 years, and participants were generally older than comparison groups. Infection, particularly pneumonia and urinary tract infection, was the most common indication and accounted for as much as 100% of patients in some studies.

Virtual-ward delivery varied considerably. Most programs combined physician home visits with remote consultations, although some used remote consultations alone. All programs provided daily physician review, often supplemented by nurse visits and additional clinical review when needed. Communication methods included video calls, telephone calls, text, chat, applications and photographs. Care could include medication administration, intravenous fluids, oxygen, nursing and diagnostics. Patients either actively measured and reported information or used automated devices, and some programs combined both approaches. Monitoring ranged from intermittent measurements, including once-daily checks, to continuous transmission of data, with respiratory rate, oxygen saturation, blood pressure, temperature and weight among the most frequently monitored variables.

Escalation during virtual-ward admission was uncommon in most reports, although rates varied. One study reported emergency-service contact in 4% of patients, while unplanned home visits ranged from 3.7% to 19.0%. Most studies reporting transfer to hospital recorded rates between 0% and 6.5%, although one reported 26%. Hospital readmission during the virtual-ward admission ranged from 0% to 2.1%. In one study, intensive-care transfers occurred in 0% of virtual-ward patients and 4% of hospital patients. These observations do not establish equivalent safety because models, populations and reporting differed.

Post-discharge emergency-department visits and readmissions were also examined. Two randomized trials reported nonsignificantly lower 30-day emergency-department visit rates for virtual wards than for hospital care: 11% versus 18% in one trial and 7% versus 13% in another. The trials also reported nonsignificantly lower 30-day readmission rates, at 11% versus 46% and 7% versus 23%, respectively. Results from nonrandomized studies were mixed. Mortality findings varied, but the two randomized trials reported no mortality difference during admission and comparable 30-day mortality between the groups. The review therefore supports cautious interpretation of these outcome measures rather than a conclusion of equivalence.

Twelve studies reported complications or adverse events. Two randomized trials reported lower adverse-event rates in virtual-ward groups, at 0% versus 9% and 9% versus 15%. A third randomized trial reported more adverse events in a remote virtual-ward arm than in an in-home hospital-at-home arm, with a mean of 6.8 versus 3.9 events per 100 patients and a difference of 2.8 per 100 patients, with a 95% confidence interval of −3.3 to 8.9. Findings from case-control and single-arm studies varied, and differences in underlying illness, medication requirements and other reported factors complicated interpretation.

The review’s principal limitation is that it was designed to map evidence rather than perform a formal assessment of effect size or risk of bias. Only three small randomized trials were included, all conducted at the same study centre, and two additional studies drew participants from those trials, reducing dataset independence. Programs generally selected clinically stable patients and were conducted mainly in well-resourced academic hospitals, limiting generalizability to other settings and higher-risk populations. Inconsistent definitions, differing eligibility rules, varied telemonitoring systems and incomplete outcome reporting also restricted comparisons. The authors concluded that virtual wards may be feasible for selected stable patients with acute conditions, but called for robust randomized trials and comprehensive, standardized cost-effectiveness analyses before wider implementation.

Subject of Research: Scoping review of technology-enabled virtual wards for adults receiving acute care

Article Title: Virtual Wards for Acute Care Patients: A Scoping Review

Article References: van Baar de Knegt, S. M. E., Zelis, N., Kaasjager, K. A. H., & Stassen, P. M. (2026). Virtual Wards for Acute Care Patients: A Scoping Review. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10682-2

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10682-2

Keywords: virtual wards, acute care, hospital at home, telemonitoring, remote monitoring, scoping review, adult patients, hospital admission, patient safety, Virtual, Wards, Acute

The demographic pressure behind the work is stark. According to United Nations projections cited in the study, the global population aged 65 and over is expected to overtake the number of children by the late 2070s, reaching 2.2 billion people. In Europe, the share of working-age individuals is shrinking while the elderly proportion climbs, and a recent meta-analysis found that roughly 46 percent of older adults worldwide live with two or more chronic conditions such as cardiovascular disease, diabetes or movement disability. Loneliness, cognitive impairment and depression compound the physical burden, making continuous, low-friction monitoring at home an increasingly attractive alternative to frequent clinical visits.

The research team, led by Azad Aghajani and Marco Ciro Liscio with colleagues at Marche Polytechnic University and EUAbout in Brussels, selected five of the most common home-monitoring devices and mapped each one across SGAM’s three dimensions: five interoperability layers running from business objectives down to physical components, domains covering the energy conversion chain, and zones representing hierarchical levels of system management from the process level up to the enterprise. In their healthcare adaptation, the elderly person’s home and its home area network occupy the customer-premises domain, while device measurements sit at the process and field levels, gateway aggregation at the station level, and monitoring and policy functions at the operation and enterprise levels. The market zone of the original model was deliberately excluded because the framework targets home care rather than electricity-market interactions.

Each layer carries a distinct technical role. The business layer defines the goals of continuous health monitoring, cost reduction and energy saving, alongside regulatory compliance with EU law, the General Data Protection Regulation, CE marking and medical device standards. The function layer covers the actual capabilities: vital-sign collection, power management, battery optimization and smart-grid integration that lets a device adjust its consumption in response to real-time energy prices. The information layer handles secure storage, encryption and interoperability with hospital information systems and electronic health records, while the communication layer governs local Bluetooth and Wi-Fi links between devices and the home gateway, wide-area connections to cloud platforms, and standards such as IEEE 11073 for personal health devices and IEC 61850 for energy-related data exchange. The component layer grounds everything in the physical hardware: sensors, microcontrollers, batteries, firmware and the IoT gateways that aggregate data.

What makes the framework conceptually interesting is that it treats healthcare devices as citizens of the smart home rather than isolated gadgets. A blood pressure monitor that knows when electricity is expensive can defer non-urgent synchronization tasks; a gateway that aggregates ECG data locally using edge computing can reduce latency and bandwidth while forwarding only clinically relevant information. The authors argue that the real value of SGAM in this context is not energy saving at the device level but the provision of a common architectural language in which heterogeneous devices, communication networks, cloud services and healthcare providers can be coordinated, with interoperability requirements identified systematically across layers rather than patched together ad hoc.

To test whether the vision makes financial sense, the team ran a cost-benefit analysis over a five-year horizon using secondary European healthcare data, manufacturer specifications and market-based estimates. The total five-year cost of owning all five devices came to 600 euros: 240 euros in purchase prices plus 360 euros in batteries and maintenance. Against this, the reference scenario assumed an annual benefit of 330 euros, derived conservatively from the lower bounds of estimated savings on travel to appointments, specialist referrals, unnecessary treatments, hospital stays, routine examinations and partial insurance costs. The resulting benefit-cost ratio was 2.75, meaning each euro spent returned 2.75 euros of assumed benefit, and the net present value, calculated with a 5 percent discount rate, turned positive in the first year and reached approximately 876 euros by year five.

Crucially, the economic result survived stress testing. In a conservative scenario with 20 percent higher costs, 20 percent lower benefits and a 7 percent discount rate, the benefit-cost ratio fell to 1.83 but the net present value remained positive at around 440 euros. Under optimistic assumptions of 20 percent lower costs, 20 percent higher benefits and a 3 percent discount rate, the ratio climbed to 4.13 with a net present value near 1,358 euros. The authors are careful to stress that these figures are scenario-based analytical assumptions, not observed savings, and that healthcare expenditure, reimbursement mechanisms and service-use patterns differ so widely across European countries that the results cannot be directly transferred to any single national system.

The energy assessment delivered perhaps the most striking number in the paper: approximately 0.12 kilowatt-hours per month for all five devices combined. Based on rated power and assumed daily use, the blood pressure monitor and smart ECG monitor, each drawing 5 watts for an assumed 20 minutes per day, dominate the total at 0.05 kilowatt-hours each per month, while the digital thermometer consumes a negligible 0.0025 kilowatt-hours. In practical terms, the entire monitoring suite uses less electricity in a month than a typical household light bulb burns in an afternoon, confirming that direct device-level energy demand is marginal and reinforcing the interpretation of SGAM as an interoperability framework rather than an energy-saving mechanism.

The study is candid about its limitations. The SGAM adaptation is conceptual and has not been validated through prototypes, simulations or real-world deployments with elderly users. The economic figures rest on secondary data and market estimates rather than measured outcomes, the energy calculations rely on assumed operating times rather than observed household consumption, and the analysis covers only five devices out of a rapidly expanding universe of connected medical technology. Potential benefits for autonomy, reassurance, continuity of care and psychological well-being are discussed as expected implications that would require dedicated studies with validated well-being indicators before they can be treated as demonstrated effects.

Even so, the framework arrives at a moment when its questions have become urgent. A SWOT analysis in the paper highlights strengths such as affordable, low-power, user-friendly devices and real-time IoT data, but also weaknesses including data security and privacy concerns, uneven infrastructure across regions, and the fact that connected monitoring suits neither all medical conditions nor all older adults. Cybersecurity threats, rapid technological change and the need to train seniors in digital skills loom as challenges. The authors point to standards-based interoperability, GDPR-compliant data governance and Regulation (EU) 2017/745 on medical devices as the regulatory backbone any deployment would need, and they call for cross-country validation involving elderly participants and healthcare professionals. If future empirical work confirms the promise, the unglamorous architecture that keeps Europe’s lights on may quietly become the scaffold for keeping its oldest citizens healthy at home.

Subject of Research: Integration of IoT-based healthcare devices within the Smart Grid Architecture Model for elderly home care in Europe

Article Title: Integration of IoT-based healthcare devices within the smart grid architecture model: a conceptual framework with economic and energy assessment for elderly care in Europe

Article References: Aghajani, A., Liscio, M. C., Scalise, L., & Sospiro, P. (2026). Integration of IoT-based healthcare devices within the smart grid architecture model: a conceptual framework with economic and energy assessment for elderly care in Europe. Frontiers in Digital Health, 8, Article 1897840. https://doi.org/10.3389/fdgth.2026.1897840

Image Credits: AI Generated

DOI: 10.3389/fdgth.2026.1897840

Keywords: IoT, smart grid, SGAM, elderly care, digital health, remote monitoring, cost-benefit analysis, energy consumption, interoperability, home healthcare, wearable sensors, Europe

The study, conducted by Lan Xiong of the First People’s Hospital of Guangyuan in Sichuan, China, retrieved records from the Web of Science Core Collection and Scopus, merged and deduplicated them, and retained 3,332 publications for analysis. Roughly 94 percent were original research articles, a signal that the field remains driven by primary experimentation rather than consolidation. The growth curve is striking: annual output stayed below 100 papers per year before 2019, then accelerated sharply, exceeding 700 papers by 2025. The trajectory fits an exponential growth model with a coefficient of determination of 0.9442, a fit the author attributes largely to concurrent advances in artificial intelligence and the normalization of remote care.

The analytical machinery behind the mapping combined several established bibliometric tools. Microsoft Excel handled deduplication and annual trend summaries; VOSviewer 1.6.20 constructed co-authorship, co-citation and keyword co-occurrence networks; CiteSpace 6.4.R1 performed clustering, timeline visualization, centrality assessment and citation burst detection; and the bibliometrix R package computed source impact indicators such as the h-index, g-index and total citations. To make sure the underlying search was trustworthy, the author validated it against a benchmark cohort of eight highly relevant papers spanning continuous ambulatory tracking, freezing-of-gait detection and smartphone-based assessment; the query retrieved seven of the eight benchmark texts, a sensitivity of 87.5 percent across both databases.

The authorship landscape reveals how strongly the field is anchored by a small group of movement-disorder specialists. Martina Mancini of Oregon Health and Science University leads the rankings with 88 publications and 3,968 citations, followed closely by her longtime collaborator Fay Horak with 76 publications and 3,571 citations. Bastiaan Bloem of Radboud University, Jeffrey Hausdorff, Walter Maetzler, Lynn Rochester and Lori Chiari round out a dense collaborative network whose intellectual roots lie in quantitative gait analysis. Institutionally, Tel Aviv University emerges as the most prolific center with 123 articles, ahead of Oregon Health and Science University’s 101, with Radboud, the University of California System and Harvard forming prominent nodes in the collaboration network.

Geographically, the United States dominates, contributing 289 papers and 14,961 total citations, with China second at 206 publications; both nations accelerated notably after 2019. But the collaboration patterns differ in an instructive way. The U.S. and China show high proportions of single-country publications, reflecting strong independent domestic research bases, while European countries, particularly Italy, Germany and the United Kingdom, act as hubs of multinational collaboration. The author argues this reflects the demands of digital phenotyping itself: building robust sensor-based tools requires not only bioengineering expertise but also movement-disorder centers with well-characterized patient cohorts, a combination that European consortia have cultivated deliberately.

The journal analysis exposes a telling asymmetry at the heart of the field. Engineering venues dominate raw output: the journal Sensors alone published 311 of the 3,332 papers, followed by the Journal of Neuroengineering and Rehabilitation and a cluster of IEEE publications. Yet the most clinically influential journal, Movement Disorders, contributed fewer than 50 primary articles to the dataset while maintaining one of the highest citation impacts in the co-citation network. Dual-map overlay of citation flows confirms robust bridges between technical clusters, such as sensors, physics and bioengineering, and clinical domains like neurorehabilitation and movement disorders. In other words, technological feasibility is racing ahead while rigorous clinical validation in top-tier neurology journals remains comparatively scarce, and correspondingly precious.

The historiographic picture the study paints is one of three overlapping eras. The most-cited foundational papers, led by Shyamal Patel’s 2009 work on monitoring motor fluctuations with wearable sensors and Arash Salarian’s 2007 quantification of tremor and bradykinesia using an ambulatory monitoring system, established whether core Parkinsonian features could be measured reliably outside the exam room at all. Early keyword clusters centered on ambulatory monitoring, inertial signal acquisition and gait detection, with citation burst analysis showing the strongest early bursts for exactly those terms. From roughly 2015 to 2020, the emphasis shifted toward algorithms: support vector machines and other classifiers for detecting freezing of gait, falls and specific motor signs, evaluated through sensitivity, specificity and agreement with clinician ratings.

The most recent phase is unmistakably artificial intelligence. Keyword burst detection from 2024 through 2026 shows strong surges for artificial intelligence, digital biomarker and, perhaps most suggestively, local field potential. Deep learning models now attempt to translate continuous free-living sensor streams into clinically meaningful metrics, including remote estimation of MDS-UPDRS scores, and smartphone-based systems have reported promising performance for quantifying overall disease severity. At the same time, a prominent cluster around deep brain stimulation has risen alongside traditional kinematic assessment, pointing toward adaptive, closed-loop neuromodulation in which external kinematics fuse with internal brain signals to tailor stimulation dynamically to symptom fluctuations. The study cautions, however, that this frontier carries real technical hurdles, including real-time artifact rejection and multimodal data integration, and that its safety and long-term efficacy demand rigorous clinical validation.

Crucially, the analysis is explicit about what its maps do and do not prove. High publication volume signifies research enthusiasm and technical feasibility, not demonstrated clinical utility. Reported performance figures vary widely and resist direct comparison because studies differ in target symptoms, sensor configurations, datasets, reference standards, disease stages and validation strategies; a high accuracy figure from one laboratory cannot be assumed to generalize. Sensor-derived metrics are also highly susceptible to confounders, including disease stage, medication-induced fluctuations, comorbidities and even where the device sits on the body. The author therefore frames bibliometric prominence as evidence that concepts like digital biomarkers have become research priorities, not as evidence that they have achieved analytical validity, clinical validity or clinical utility, distinctions that regulatory initiatives such as digital endpoint qualification and the Critical Path for Parkinson’s Consortium are working to establish.

The roadmap that emerges from the study is less about building new gadgets and more about building trust. The author calls for standardized data collection and reporting protocols covering device placement, sampling frequency, preprocessing, task definitions and missing-data handling; multicenter real-world validation across diverse populations and medication cycles; and longitudinal studies that test whether digital measures actually track clinically meaningful change over time rather than merely agreeing with clinic-based scales at a single moment. Workflow integration is framed as the decisive bottleneck: clinicians need concise, interpretable summaries with uncertainty estimates rather than raw sensor streams, and patients need systems that minimize burden and protect privacy. Multimodal data fusion combining movement signals with physiology, imaging, electrophysiology and patient-reported outcomes, along with cautious exploration of closed-loop stimulation, marks the field’s higher-risk frontier. If the past twenty years were about proving sensors could see Parkinson’s disease in the wild, the next phase, on this evidence, will be about proving that what they see can safely change what doctors do.

Subject of Research: Bibliometric mapping of wearable sensor and digital health research in Parkinson's disease from 2005 to 2026

Article Title: Digital health meets Parkinson’s disease: a bibliometric exploration of wearable sensors research and emerging frontiers (2005–2026)

Article References: Xiong, L. (2026). Digital health meets Parkinson’s disease: a bibliometric exploration of wearable sensors research and emerging frontiers (2005–2026). Frontiers in Neuroinformatics, 20, Article 1937585. https://doi.org/10.3389/fninf.2026.1937585

Image Credits: AI Generated

DOI: 10.3389/fninf.2026.1937585

Keywords: Parkinson's disease, wearable sensors, digital biomarkers, bibliometric analysis, artificial intelligence, remote monitoring, freezing of gait, deep brain stimulation, machine learning, gait analysis, digital health, closed-loop neuromodulation

The work is part of a larger pragmatic randomized trial called InSPIRED, short for Implementation Strategies for Self-Measured Blood Pressure Monitoring in Racially and Ethnically Diverse Populations. The trial registered as NCT06871462 spans six community health centers within two safety-net healthcare systems, the San Francisco Health Network and Alameda Health System. Before any intervention could be tested, the team needed to understand precisely where the process of home blood pressure monitoring breaks down, both for patients who are asked to measure themselves and for clinicians who are asked to prescribe, train, and document. Their answer was to borrow methods from human-centered design, the same iterative, empathy-driven approach that technology companies use to build products around real user behavior.

The patient-facing side of the research was extensive. The investigators conducted nine focus groups and eighteen individual interviews in English, Spanish, and Chinese, reaching a total of sixty patients. This multilingual design mattered: safety-net populations include large numbers of patients whose primary language is not English, and implementation strategies built only around English-language materials routinely fail them. The interviews probed three domains: the challenges patients face when trying to engage with home blood pressure monitoring, their preferences for training and hypertension education, and their attitudes toward involving peers, family members, or friends in their hypertension care.

The findings on training were strikingly consistent. Patients said they preferred in-person, language-concordant instruction on how to perform self-measured blood pressure monitoring and how to use mobile health applications that support it. A single demonstration at the pharmacy counter or a printed leaflet was not enough. Patients wanted ongoing access to training resources, such as videos they could revisit whenever they forgot a step or a family member needed to learn the technique. This preference for refreshable, on-demand education reflects a well-known problem in digital health: initial training decays quickly, and without reinforcement, correct technique, including proper cuff placement, resting posture, and timing of measurements, drifts within weeks.

Perhaps the most socially interesting result concerned peer support. Patients expressed genuine enthusiasm for joining virtual or in-person support groups focused on hypertension, provided the groups were led by trained research staff and used vetted discussion content. The idea of harnessing community for a chronic condition that is otherwise managed alone at home resonated with participants. But when it came to family and friends, patients drew a clear boundary. Most preferred low-touch approaches that would not burden their loved ones, such as giving family members access to the same educational materials the patients received, rather than asking relatives to take on active caregiving tasks like tracking readings or managing medications. The distinction is subtle but important for intervention designers: patients want their social networks informed, not conscripted.

On the clinic side, the researchers convened seven focus groups with sixty-two clinicians to map the obstacles that arise across the entire self-measured blood pressure workflow. The list was long and revealing. Clinicians described the absence of standardized workflows for educating patients about home monitoring, uncertainty about how to confirm that a patient’s home device is clinically validated and fitted with the correct cuff size, difficulty training patients on measurement technique within the constraints of a brief visit, and inconsistent documentation of monitoring plans in the electronic health record. Each of these friction points may seem minor in isolation, but together they form a gauntlet that a home monitoring program must survive, and in busy, under-resourced clinics, the path of least resistance is often simply not to start.

Device validation deserves particular attention because it is a technical detail with real clinical consequences. Blood pressure monitors sold for home use vary enormously in accuracy, and inaccurate devices produce readings that can lead to misdiagnosis or inappropriate treatment. Clinicians in the focus groups flagged that confirming validation and appropriate cuff size, which differs by arm circumference, was a recurring and poorly supported task. Any implementation strategy that ignores this step risks building a monitoring program on unreliable data.

Having gathered this evidence, the team prioritized pragmatic, low-cost strategies built around two pillars. The first was training care teams and clinical champions, embedding expertise within each clinic so that knowledge about validated devices, proper technique, and patient education does not depend on a single enthusiastic individual. The second was a suite of electronic health record tools designed to smooth the clinical workflow. These included reminders that surface the core teaching content for self-measured blood pressure monitoring and instructions for validating home monitors, standardized documentation templates known as smartphrases that let clinicians record monitoring plans quickly and consistently, and patient-facing instructions in the patient’s own language that clinicians can print or send with minimal effort.

The elegance of the approach lies in its economy. Rather than proposing expensive new platforms or additional staffing that safety-net systems cannot sustain, the co-design process surfaced interventions that piggyback on infrastructure already in place: the electronic health record that clinicians already use, the educational materials that can be produced once and reused indefinitely, and the social networks that patients already trust. Human-centered design served as the filter that separated plausible-on-paper strategies from ones that patients and clinicians said they would actually adopt, and the multilingual engagement ensured the resulting tools would work for the diverse populations these centers serve.

The study, funded by the Agency for Healthcare Research and Quality with additional support from the National Institutes of Health, offers a template that extends beyond blood pressure. As remote monitoring expands to diabetes, heart failure, and pregnancy-related hypertension, the same implementation challenges will recur: who trains the patient, how the technique is verified, how the data flows into the record, and how the plan is communicated. The InSPIRED team’s answer, co-design with patients and clinicians in their own languages before building anything, is a deceptively simple prescription. Whether the co-designed strategies ultimately raise blood pressure control rates will be answered by the ongoing randomized trial, but the study already demonstrates that the people closest to the problem can articulate solutions that experts might never imagine, from peer support groups with vetted content to the quiet insistence that family should be informed but not burdened.

Subject of Research: Co-designed implementation strategies for self-measured blood pressure monitoring in community health centers

Article Title: Co-Designing Pragmatic implementation strategies to improve adoption of self-measured blood pressure monitoring by patients and clinicians in community health centers

Article References: Kim, H. C., Li, J., Garcia, F., Larreynaga, J., Luna, I., Mejia-Lopez, A., Yang, A., Curtis, N. C., Lyles, C. R., Sarkar, U., & Khoong, E. C. (2026). Co-Designing Pragmatic implementation strategies to improve adoption of self-measured blood pressure monitoring by patients and clinicians in community health centers. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15825-z

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15825-z

Keywords: hypertension, self-measured blood pressure, community health centers, human-centered design, implementation science, electronic health records, health equity, patient education, digital health, safety-net care, pragmatic clinical trial, remote monitoring

The research, led by Chao Zhu and Daniel Merlo together with colleagues from institutions across Australia, Europe and beyond, drew on two rich data sources. Clinical information came from MSBase, a large international registry that tracks outcomes in people with multiple sclerosis over many years, while cognitive measurements came from MSReactor, a computerised battery of cognitive tests that patients can complete remotely. The study population consisted of 746 patients with relapsing-remitting multiple sclerosis, whose records spanned the period from February 2016 to September 2022, with a median follow-up of 3.2 years. During that window, the researchers tracked which patients experienced confirmed disability progression, the clinical milestone that marks a turning point in the disease course.

The central challenge the team faced was one of dimensionality. A single session of computerised cognitive testing produces a torrent of reaction time data, with each trial of each task yielding a measurement precise to the millisecond. When those sessions are repeated serially over months and years, the resulting dataset becomes a sprawling, irregularly sampled time series that resists conventional statistical analysis. Traditional approaches collapse this richness into summary statistics, such as the mean reaction time per test, and in doing so discard much of the temporal texture that may carry the earliest signals of neurological change. The researchers suspected that this discarded texture was precisely where the predictive value lay.

Their solution was as elegant as it was unconventional. Rather than treating the reaction time data as numbers to be crunched, they treated it as something to be seen. Serial reaction time measurements from three distinct cognitive tasks were encoded into multicolour images using the RGB colour scheme familiar from digital photography. Psychomotor function, measured by a task labelled R, was mapped to one colour channel; attention, labelled G, to another; and working memory, labelled B, to the third. Each patient’s cognitive history thus became a visual artefact, a kind of portrait of their brain’s processing speed over time, in which patterns of variability, slowing and fluctuation could be rendered visible to an algorithm designed to detect them.

Once the images were constructed, the team deployed a convolutional neural network, the same class of algorithm that powers facial recognition and medical image analysis, to extract the salient features from each patient’s cognitive portrait. These learned features were then combined with standard clinical variables, such as demographic information and disease history, and fed into a Transformer-based survival model the researchers named MS-TranSurv. Survival models are a staple of clinical statistics, designed to predict the time until an event occurs, but the Transformer architecture, originally developed for processing sequential data in natural language, allowed the model to weigh the relative importance of different pieces of information flexibly and in context. The output was a personalised estimate of the time to confirmed disability progression.

Evaluating such a model requires rigorous benchmarks, and the team compared MS-TranSurv against several formidable competitors. These included Dynamic DeepHit and Recurrent Deep Survival Machines, both state-of-the-art deep learning approaches to survival prediction, as well as a classical Cox proportional hazards model built on clinical variables alone, and a stripped-down version of MS-TranSurv that used only mean test values rather than the full image-encoded data. Performance was assessed with three complementary metrics: the concordance index, which measures how well the model ranks patients by risk; the integrated Brier score, which captures calibration, or how closely predicted probabilities match observed outcomes; and the time-dependent area under the receiver operating characteristic curve, which gauges classification accuracy at specific time points.

The results were encouraging, if measured. MS-TranSurv achieved a concordance index of 0.61, with a 95 percent confidence interval of 0.54 to 0.68, indicating slightly better discrimination than the benchmark models. Its time-dependent area under the curve reached 0.74, with a confidence interval of 0.63 to 0.85, while its integrated Brier score of 0.24, spanning 0.16 to 0.32, demonstrated calibration comparable to the alternatives. Notably, the version of the model that consumed individual test-level data, preserving the full granularity of the reaction time recordings, outperformed the variant relying on summary measures. This finding vindicates the team’s core intuition: the fine-grained temporal structure of cognitive performance carries genuine predictive information that averages destroy.

It is worth being clear about what these numbers do and do not mean. A concordance index of 0.61 reflects modest, not spectacular, discrimination, and the wide confidence intervals reveal the uncertainty inherent in a cohort of this size. The authors are candid that the model’s advantage over existing approaches is incremental rather than transformative. Yet the significance of the work lies less in the headline metrics than in the demonstration of feasibility. Serial cognitive assessment is inexpensive, non-invasive and can be administered remotely, making it one of the few monitoring tools that patients could realistically deploy from home at high frequency. Proving that this data stream can be converted into survival-based risk predictions opens a door that conventional analysis had kept shut.

The clinical implications extend in several directions. For neurologists managing relapsing-remitting multiple sclerosis, a validated risk prediction tool could sharpen decisions about when to escalate disease-modifying therapy, moving beyond reactive treatment changes after progression becomes evident toward proactive intervention while the window for preventing irreversible damage remains open. For clinical trial designers, the model offers a route to enrichment, the practice of recruiting participants at higher risk of the outcome being studied, which reduces trial size and duration and accelerates the evaluation of new therapies. The framework’s generality is perhaps its most exciting feature: the image-encoding strategy could be applied to other high-dimensional digital biomarkers, from wearable sensor streams to speech recordings, wherever longitudinal data outstrips the reach of traditional statistics.

The study also underscores a broader shift in neurology toward remote, continuous monitoring. Cognitive decline often precedes measurable physical disability in multiple sclerosis, and subtle changes in processing speed may flag disease activity that standard clinical examinations miss. A patient completing a brief computerised battery at home every few months generates a longitudinal record of brain function that no clinic visit schedule could match. Combined with machine learning methods capable of reading that record in full resolution, such monitoring could transform risk stratification from an art informed by occasional snapshots into a science built on dense, personalised data. The MSBase and MSReactor cohorts that made this study possible hint at the scale of what such data ecosystems could ultimately deliver, and the research team’s framework offers a template for turning the digital exhaust of routine care into clinically actionable foresight.

Subject of Research: Deep learning prediction of disability progression in relapsing-remitting multiple sclerosis using image-encoded cognitive reaction time data

Article Title: Strategies for integrating artificial intelligence and cognitive assessment to predict disability progression in relapsing-remitting multiple sclerosis: A model development study

Article References: Zhu, C., Zhang, X., van der Walt, A., Taylor, B., Monif, M., Kalincik, T., Lechner-Scott, J., Buzzard, K., Kilpatrick, T., Barnett, M., Zhou, Z., Jokubaitis, V., Gresle, M., Darby, D., Mehta, D., Ge, Z., Butzkueven, H., & Merlo, D. (2026). Strategies for integrating artificial intelligence and cognitive assessment to predict disability progression in relapsing-remitting multiple sclerosis: A model development study. PLOS Digital Health, 5(9), e0001722. https://doi.org/10.1371/journal.pdig.0001722

Image Credits: AI Generated

DOI: 10.1371/journal.pdig.0001722

Keywords: multiple sclerosis, artificial intelligence, deep learning, cognitive assessment, disability progression, survival analysis, digital biomarkers, reaction time, Transformer model, remote monitoring, clinical trial enrichment, MSBase registry

Elan’s central move is to shift the analytical frame from people who have adequate care to what the paper calls care-marginalized populations: those who are structurally excluded from sufficient human care. This group is far larger than public debate usually acknowledges. The World Health Organization projects a widening global shortfall of health workers, and OECD analyses of the coming demographic crunch describe care systems stretched to breaking by aging populations. In China alone, national statistics record hundreds of millions of older adults alongside shrinking family sizes, and surveys of internet use document vast numbers of elderly people living alone in empty-nest households. For family caregivers, longitudinal studies of end-of-life care show exhaustion, depressive symptoms, and the collapse of working lives under the weight of unpaid labor. When the premise of abundant human care fails, Elan argues, the best the traditional critique can offer is to frame AI as harm reduction, a second-best option for people with no better choice. The paper contends that even that framing concedes too much ground.

To rebuild the ethical analysis from the ground up, Elan introduces a Care Priority Hierarchy, borrowing structural logic from classic motivation theories such as Maslow’s hierarchy of needs and Alderfer’s empirical work on human needs. The idea is that ethical evaluation should begin at the most fundamental levels of care rather than at the most philosophically glamorous ones. At the base sits functional care: the actual physical and medical work of keeping a person alive and healthy. Above it come non-burdensomeness, meaning the relief of crushing strain on both caregivers and care recipients, and then dignity, the preservation of self-respect and personhood. Only at the top of the hierarchy does relational authenticity, the quality that has absorbed so much of the academic debate, appear. The argument is not that authenticity does not matter, but that it is incoherent to litigate the authenticity of a relationship when the lower floors of the building are missing.

At the level of functional care, the technical case for AI is increasingly concrete. Large language models have now been tested in randomized, preregistered trials as medical assistants for the general public, with results published in Nature Medicine in 2026, and comparative studies in The Lancet Digital Health and the Journal of Medical Internet Research have evaluated the diagnostic and triage accuracy of frontier models against physician performance. Family caregivers, who frequently lack professional medical training and whose health literacy strongly predicts how well they perform clinical tasks at home, could draw on this knowledge base for medication management, wound care, and symptom monitoring. Sensor-equipped remote monitoring systems, reviewed systematically for patients with Alzheimer’s disease and related dementias, can detect deterioration that exhausted human observers miss. One striking piece of hard-outcome evidence comes from a pragmatic randomized clinical trial published in the International Journal of Nursing Studies, in which a wearable patient sensor on hospital wards significantly reduced pressure injuries. Elan is careful to note that this effect has not yet been directly tested in home settings, but the trajectory is clear: machines can supply medical competence that non-professional caregivers lack, and, as embodied care robots mature, perform the physical body-work that care requires.

The second and third levels of the hierarchy, burden and dignity, are where the paper makes its most provocative claims. A key concept here is self-perceived burden, defined in a qualitative systematic review by Saji and colleagues as the patient’s experience of feeling useless, a failure, or out of control. People who feel like a burden sacrifice their own needs to spare their caregivers, a sacrifice that paradoxically increases total suffering. Meta-analyses link subjective caregiver burden to depressive symptoms in carers of older relatives, and research on disabled patients shows that self-perceived burden mediates the relationship between meaning in life and dignity. Elan’s insight is that AI care can dissolve this psychological mechanism at its root: a care recipient who knows that a machine does not tire, does not sacrifice its career, and does not pay a personal cost for every glass of water delivered no longer needs to ration its own needs. The burden disappears not by being hidden but by being structurally dissolved.

Dignity, long the trump card of the anti-robot argument, is similarly re-examined. Classic papers by Sharkey and by Sparrow and Sparrow warned that delegating intimate care to machines would humiliate older people, and Felber and colleagues have used social dignity as a yardstick for robotic assistance. But Elan points to the opposite side of the ledger: intimate body-work, such as bathing, toileting, and lifting, can compromise dignity on both sides, embarrassing the recipient and dehumanizing the caregiver who performs it. The concept of beneficent dehumanization, developed by Palmer and Schwan in the journal Bioethics, captures the idea that shame-induced barriers to medical care can actually be lowered when a machine rather than a human performs intimate tasks. Empirical attitude research supports the reframing: a study in the International Journal of Social Robotics found that care-dependent people are less averse to care robots than the general population, suggesting that the strongest objections come from those who will never need the technology. Non-randomized interventional work on care robots has also documented reductions in physical burden and pain for caregivers, and meta-analytic evidence on mechanical lifting devices shows substantial reductions in musculoskeletal injuries among health personnel.

In the relational domain, Elan argues that AI supports human care both indirectly and directly. Indirectly, it restores the caregiver capacity that scarcity exhausts: a conversational AI that answers an Alzheimer’s caregiver’s questions at three in the morning, or a monitoring system that watches a sleeping parent, returns to the human caregiver the time and emotional reserves needed for genuinely human connection. Studies of conversational AI for dementia caregivers and qualitative work mapping caregiver needs to chatbot design document exactly this kind of relief. Directly, AI can offer attention free of imposition anxiety. Research published in the Journal of Consumer Research found that AI companions reduce loneliness, and a qualitative study of empty-nest elderly users of AI chatbots published in BMC Public Health in 2026 describes users who find it easier to talk to a system that they know has no feelings to hurt and no schedule to disrupt. For someone who has spent years feeling like a burden, an interlocutor who cannot be burdened changes the emotional physics of every interaction.

None of this means the risks vanish, and Elan does not pretend otherwise. The paper acknowledges documented failure modes of conversational systems, including the sycophancy incident OpenAI disclosed for GPT-4o, psychiatric warnings about chatbot-generated delusions in people prone to psychosis, and the sharp critique by Muldoon and Parke that commercial AI companions exploit loneliness and commodify intimacy. These dangers are real, but Elan treats them as design and governance problems rather than reasons to withhold care from people who currently have none. The paper proposes a deployment framework ordered by technological maturity, rolling out systems as their reliability is demonstrated, with two foundational constraints: non-extractive design, so that systems do not monetize the vulnerability of lonely users, and economic accessibility, so that AI care does not become a luxury good for the wealthy while the care-marginalized remain excluded.

The deepest contribution of the paper may be methodological rather than technological. Elan insists that ethical evaluation must be grounded in the human care actually available, not in idealized assumptions of sufficiency. Judged against an imaginary world of attentive human caregivers, AI care will always look like a loss. Judged against the real world of overworked nurses, exhausted daughters, absent services, and isolated elders, it can look like a structural uplift: across every actual care configuration, adding AI expands rather than contracts the total pool of caregiving capacity. The replacement worry, on this reading, rests on a misleading binary. The choice is not between a human hand and a robotic one; it is between a robotic hand and no hand at all, and for a growing share of the world’s population, that is the choice actually on the table.

Subject of Research: Ethical evaluation of AI caregiving for care-marginalized populations

Article Title: Beyond harm reduction: dignity, burden, and the genuine advantage of AI caregiving

Article References: Elan, T. G. (2026). Beyond harm reduction: dignity, burden, and the genuine advantage of AI caregiving. AI & SOCIETY. https://doi.org/10.1007/s00146-026-03319-9

Image Credits: AI Generated

DOI: 10.1007/s00146-026-03319-9

Keywords: AI caregiving, care ethics, care robots, self-perceived burden, dignity, care-marginalized populations, harm reduction, large language models, remote monitoring, caregiver burden, loneliness, AI & Society

In a study published in the journal Cluster Computing, Samia A. El-Moneim Kabel and Walid El-Shafai proposed a new compression method that combines the Discrete Wavelet Transform (DWT) with fractal encoding. The approach is designed to exploit the self-similar characteristics inherent in FPCG signals. By identifying recurring patterns within the data, the method aims to represent these patterns using compact transformation information rather than storing the original coefficient blocks. This hybrid strategy seeks to balance high compression ratios with acceptable reconstruction quality for clinical use.

The proposed method begins by applying the Discrete Wavelet Transform to decompose the FPCG signal. This process separates the signal into approximation coefficients and detail coefficients. The approximation coefficients, which capture the broader trends of the signal, are then subjected to fractal encoding. This step involves identifying recurrent signal patterns and representing them through mathematical transformations. The detail coefficients, which contain finer variations, are preserved separately to ensure that important signal features are not lost during the compression process.

During the decompression phase, the method employs iterative fractal decoding to reconstruct the approximation coefficients from the compact transformation data. The preserved detail coefficients are then combined with the reconstructed approximation coefficients through an inverse DWT process. This reconstruction step aims to restore the original signal structure as closely as possible. The entire workflow is designed to be computationally efficient, addressing the real-time processing requirements often necessary in fetal monitoring applications.

The authors implemented the proposed method in MATLAB and evaluated its performance using FPCG signals. The evaluation metrics included compression ratio, mean square error, peak signal-to-noise ratio, compression time, and decompression time. These metrics provide a comprehensive view of both the efficiency of the data reduction and the quality of the reconstructed signal. The study utilized publicly available data, and the authors noted that no new datasets were generated or analyzed during the research, as the work focused on algorithmic development and simulation.

Experimental results indicated that the DWT-assisted fractal compression method achieves substantial data reduction. The study reported that the method maintains acceptable reconstruction quality, suggesting that diagnostically relevant information is preserved despite the significant reduction in file size. The authors highlighted the potential of this approach for efficient storage and transmission of FPCG signals in fetal health monitoring applications. The findings suggest that the method could be particularly useful in scenarios where bandwidth is limited, such as remote patient monitoring.

The research builds upon previous work in biomedical signal compression, which has explored various techniques including wavelet transforms and compressed sensing. Earlier studies have demonstrated the utility of wavelet-based methods for reducing the size of phonocardiogram signals. However, the integration of fractal encoding specifically targeting the approximation coefficients of the DWT decomposition is a distinct contribution of this work. The authors acknowledge the support of the Tanta High Institute of Engineering and Technology and the Automated Systems and Computing Lab at Prince Sultan University in the development of this research.

It is important to note that this study presents a proposed algorithm and its simulation results. The method has not yet been validated in clinical trials or real-world deployment scenarios. The authors did not receive external funding for this research and declared no competing interests. The study did not involve human participants, as it relied on publicly available data, and therefore ethical approval for human subject research was not required. The focus remains on the technical feasibility and performance metrics of the compression algorithm.

The potential application of this compression method extends to improving the infrastructure for remote fetal monitoring. By reducing the data size, the method could facilitate the transmission of FPCG signals over low-bandwidth connections, enabling more widespread access to fetal heart monitoring. This could be particularly beneficial in regions with limited healthcare infrastructure. However, further research is needed to assess the method’s robustness in diverse clinical environments and its impact on diagnostic accuracy in real-time settings. The study provides a foundation for future work in optimizing biomedical signal compression for IoT applications.

In conclusion, the DWT-assisted fractal compression method offers a promising approach to the challenge of storing and transmitting fetal phonocardiography signals. By leveraging the self-similarity of FPCG data through fractal encoding and the frequency decomposition capabilities of the DWT, the method achieves significant data reduction while maintaining signal quality. The results suggest that this hybrid technique could play a role in the development of more efficient remote fetal monitoring systems. As the field of biomedical signal processing continues to evolve, such methods may contribute to making fetal heart monitoring more accessible and efficient.

Subject of Research: Biomedical Signal Processing

Article Title: DWT-assisted fractal compression for efficient storage and transmission of fetal phonocardiography signals

Article References: Kabel, S. A. E.-M., & El-Shafai, W. (2026). DWT-assisted fractal compression for efficient storage and transmission of fetal phonocardiography signals. Cluster Computing, 29(13), Article 764. https://doi.org/10.1007/s10586-026-06501-2

Image Credits: AI Generated

DOI: 10.1007/s10586-026-06501-2

Keywords: Fetal Phonocardiography, Signal Compression, Discrete Wavelet Transform, Fractal Encoding, Remote Monitoring, Biomedical Engineering, DWT-assisted, fractal, compression, efficient, storage, transmission

The letter, written by Nashmia Faraz, Haider Imran and Abdul Basit of the Department of Medicine at Foundation University Medical College in Islamabad, Pakistan, takes aim at the gap between objective and subjective measures of adherence in oral appliance therapy. Published in September 2026, the correspondence responds to emerging longitudinal evidence on how adults with obstructive sleep apnea actually use their appliances over a full year, and it argues that the field must refine how adherence is defined, measured and interpreted before the therapy’s real-world effectiveness can be judged fairly.

The concern is not academic hair-splitting. An oral appliance that sits in a drawer delivers no therapeutic benefit, no matter how well it was designed or how effectively it advanced the jaw in a laboratory titration study. Adherence is the hinge on which the entire treatment turns. For CPAP, this lesson was learned early and painfully: studies famously showed that early patterns of use in the first days and weeks strongly predicted long-term adherence, prompting sleep medicine to invest heavily in objective compliance monitoring, telehealth coaching and early intervention programs. Modern CPAP machines log every hour of use, and those data streams are now woven into routine care. Oral appliance therapy, by contrast, has largely depended on what patients report at follow-up visits.

Self-report is a notoriously fragile foundation for clinical decisions. Patients may genuinely believe they wear their devices more than they do, because nights of fragmented sleep blur memory and because social desirability nudges people toward the answers they think their clinicians want to hear. The literature cited in the letter makes the scale of the discrepancy unmistakable. A landmark 2013 study published in Chest by Dieltjens and colleagues compared objectively measured compliance, captured by embedded microsensors, with self-reported compliance among patients using mandibular advancement devices for sleep-disordered breathing. The objective data revealed substantially lower usage than patients reported, exposing a gap large enough to distort outcome studies, cost-effectiveness analyses and clinical audit alike.

Embedded microsensors have since become the technical benchmark for objective adherence measurement in oral appliance therapy. These tiny temperature-sensitive chips sit inside the appliance and register when the device is actually in the mouth, distinguishing genuine use from mere possession. When the appliance is inserted, oral temperature triggers the sensor; when it rests on a bedside table, no temperature change is recorded. The approach mirrors the objective compliance chips that transformed CPAP monitoring, and it offers sleep medicine something it has long lacked for dental devices: a truthful, time-stamped record of real-world use patterns, including how many nights per week the appliance is worn and for how many hours per night.

The new longitudinal pilot data that prompted the letter tracked both objective and subjective adherence in adults with obstructive sleep apnea over one year, providing a rare window into how usage evolves well beyond the initial adaptation period. The corresponding letter argues that such data should push the field toward a more nuanced adherence framework, one that distinguishes between objective device use, patient-perceived use and clinical response, rather than collapsing them into a single self-reported figure. The authors, who conceptualized and drafted the correspondence with no external funding and no competing interests, position their contribution as a call to tighten the methodological standards of oral appliance research.

Why does this refinement matter now? Oral appliance therapy is expanding rapidly. Clinical guidelines recommend it for patients with mild to moderate obstructive sleep apnea and for those with severe disease who cannot tolerate or decline CPAP. Dental sleep medicine has grown into a distinct subspecialty, and the global market for mandibular advancement devices continues to climb as obesity rates and disease prevalence rise. Every prescription implicitly assumes that the device will be worn consistently. If adherence measurement lags behind prescription volume, the field risks both overtreatment, with devices dispensed to patients who will never use them, and undertreatment, with genuine adherence problems overlooked until symptoms return or cardiovascular risk quietly accumulates.

The letter also draws an instructive parallel with the CPAP literature, including the 2007 study by Budhiraja and colleagues in the journal Sleep demonstrating that early CPAP use identified subsequent long-term adherence. That finding reshaped clinical practice, motivating early follow-up and, eventually, remote monitoring programs that flag struggling patients within days. For oral appliances, the analogous evidence base is younger and thinner, but studies such as the 2022 investigation by Kwon and colleagues in the Journal of Sleep Research show that remote monitoring and structured feedback can measurably improve objective compliance with mandibular advancement devices. Together, these strands of evidence suggest that objective adherence measurement is not merely a research nicety; it is the enabling technology for the same kind of proactive, data-driven care that rescued CPAP adherence a generation ago.

The technical challenges, however, are real. Microsensor data must be validated against true wear events, sensors can fail or be damaged during cleaning, and different sensor generations may not produce comparable metrics. The field lacks universally accepted adherence thresholds for oral appliances, whereas CPAP benefited from widely used conventions such as the Medicare definition of four hours per night on seventy percent of nights, itself a contested standard. Without consensus definitions, meta-analyses of appliance effectiveness will continue to mix studies whose adherence figures mean different things, blurring genuine differences in therapeutic efficacy with differences in measurement practice. The authors of the letter imply that resolving this definitional tangle is a prerequisite for the next generation of oral appliance research.

What would refined adherence assessment look like in practice? The ingredients are already on the table: objective sensor-derived metrics reporting nights and hours of use, patient-reported measures captured with validated questionnaires, and clinical outcomes such as the apnea-hypopnea index on follow-up polysomnography or home testing. Longitudinal designs, like the one-year pilot study that sparked the correspondence, add the crucial temporal dimension, revealing whether adherence decays over months and which patients are at greatest risk of abandoning therapy. Integrating these data streams into electronic health records and telemedicine platforms could finally give dental sleep medicine the feedback loops that clinicians need, allowing early, targeted interventions before non-adherence becomes entrenched. As oral appliance therapy takes its place alongside CPAP in mainstream sleep medicine, the message from Islamabad is clear: the therapy can only be as good as the evidence that patients are actually using it, and measuring that use honestly is the field’s next essential task.

Subject of Research: Objective versus subjective adherence assessment in oral appliance therapy for obstructive sleep apnea

Article Title: Refining adherence assessment in oral appliance therapy for obstructive sleep apnea

Article References: Faraz, N., Imran, H., & Basit, A. (2026). Refining adherence assessment in oral appliance therapy for obstructive sleep apnea. Journal of Clinical Sleep Medicine, 22(1), Article 158. https://doi.org/10.1007/s44470-026-00176-7

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00176-7

Keywords: obstructive sleep apnea, oral appliance therapy, mandibular advancement device, adherence measurement, microsensors, CPAP, sleep medicine, self-reported compliance, remote monitoring, dental sleep medicine, Journal of Clinical Sleep Medicine, Refining